Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioInvent International
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
July 28, 2026
BioInvent’s BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
July 17, 2026
BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
June 11, 2026
BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
June 11, 2026
BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
May 12, 2026
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
May 12, 2026
Resolutions at BioInvent’s Annual General Meeting 2026
April 29, 2026
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
April 29, 2026
BioInvent International AB: Interim Report January – March 2026
April 29, 2026
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
April 21, 2026
1
2
Next Page
→